The first clinical study on a Fab targeting carbonic anhydrase 6 (CA6) epitope of MUC1 reported the safety of this probe in an ovarian cancer patient, and the probe correctly reflected the low tumor expression of CA6 observed in IHC (370). The gene discussed is CA6; the disease is neoplasm.